Neurocrine Access Support for CRENESSITY is a free, comprehensive program for you, your staff, and your patients. Prescribe CRENESSITY by submitting a completed Enrollment Form and clinical documentation to PANTHERx Rare, the exclusive specialty pharmacy that distributes CRENESSITY.

Financial support options

Commercially insured patients?

CRENESSITY Savings Program: Patients can pay $0 out of pocket for their CRENESSITY prescription if they have commercial insurance.*

Insurance delaying a patient’s new prescription?

QuickStart Program: In the event of coverage delays, patients can initiate treatment with 30 days of free CRENESSITY.*

Patients without insurance or resources?

Patient Assistance Program (PAP): This program is designed to help patients who do not have insurance, whose insurance doesn’t cover CRENESSITY, or who lack the financial resources to pay for their prescription. PAP provides medication at no cost.*

Changes in your patient’s coverage?

Bridge Program

Neurocrine Access Support will help ensure there is no disruption in treatment with CRENESSITY.* It’s important that you or your patient inform your Care Coordinator of any insurance updates as soon as possible.

Learn more about
Neurocrine Access Support

*Additional terms and conditions apply.

Our commitment is simple and unwavering: to ensure every patient who needs CRENESSITY can start and continue treatment.

Real patient and caregiver using Neurocrine Access Support.

Dosing

Review the dosing and administration information for CRENESSITY.

Videos

Hear directly from endocrinologists and patients about their CRENESSITY experience.

Get in Touch

CAH=congenital adrenal hyperplasia; GC=glucocorticoid.

INDICATION

CRENESSITY (crinecerfont) is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

CONTRAINDICATIONS

CRENESSITY is contraindicated in patients with hypersensitivity to crinecerfont or any excipients of CRENESSITY.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions. A hypersensitivity reaction, including throat tightness, angioedema, and generalized rash, occurred in a subject after 3 days of treatment with CRENESSITY. If a clinically significant hypersensitivity reaction occurs, initiate appropriate therapy and discontinue CRENESSITY.

Risk of Acute Adrenal Insufficiency or Adrenal Crisis with Inadequate Concomitant Glucocorticoid Therapy. Acute adrenal insufficiency or adrenal crisis, which is potentially life-threatening, can occur in patients with underlying adrenal insufficiency who are on inadequate daily glucocorticoid doses, especially in situations associated with increased cortisol need, such as acute intercurrent illness, serious trauma, or surgical procedures. Continue glucocorticoids upon initiation of and during treatment with CRENESSITY. Do not reduce the glucocorticoid dose below the dose required for cortisol replacement. Patients should continue to use stress dosing of glucocorticoids in cases of increased cortisol need.

ADVERSE REACTIONS

In adult patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia.

In pediatric patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are headache, abdominal pain, fatigue, nasal congestion, and epistaxis.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths:

CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.

Please see full Prescribing Information.